In clinical trials the treatment — which involves extracting individual patients» immune T - cells, modifying them to seek out tell - tale biological markers associated with blood cancers like aggressive lymphoma, and then pumping
those modified killer cells back into the body — has shown major promise, in some cases eliminating all signs of the cancer in patients six months after treatment.
For every
modified T
cell infused into the patients» blood, at least 1000 tumor
cells were killed, leading the researchers to dub the T
cells «serial
killers.»